Streetbeat News

Stock Prices

MBRX

Moleculin Biotech, Inc. (NASDAQ: MBRX) announced plans for a pivotal, adaptive Phase 3 clinical trial (MIRACLE trial) for the possible accelerated approval of Annamycin in combination with Cytarabine for treating relapsed or refractory AML. The decision follows a positive discussion with the FDA.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:36 pm

ARM

AZN

EWU

FXB

HSBC

RIO

SHEL

The Bank of England (BoE) reduced its key interest rate by 25 basis points to 5%, marking the first cut in over four years. The decision was divided among the Monetary Policy Committee members. The BoE expects inflation to rise to 2.75% later this year but fall below target in the next two years. The British pound fell 0.5% against the dollar, while UK equities remained flat. US-listed British companies showed mixed premarket performances.

Portfolio Pulse from Piero Cingari

August 01, 2024 | 12:35 pm

COIN

Vice President Kamala Harris is pivoting towards the cryptocurrency sector to gain support from Silicon Valley's tech community, as her chances of winning the 2024 presidential race stand at 43% according to Polymarket. Her campaign has reached out to Bitcoin advocate Mark Cuban and is considering meetings with industry giants like Ripple, Coinbase, and Circle.

Portfolio Pulse from Murtuza Merchant

August 01, 2024 | 12:35 pm

CPB

Campbell Soup Company (NYSE:CPB) will transfer its stock exchange listing from the NYSE to the Nasdaq Global Select Market on August 16, 2024. The company will continue to trade under the 'CPB' ticker symbol and will join the Nasdaq Composite index. Campbell will also hold an Investor Day on September 10, 2024, at Nasdaq MarketSite.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:35 pm

SMP

Standard Motor Products (SMP) reported Q2 2024 adjusted EPS of $0.98, beating the estimate of $0.78. Sales were $389.829 million, surpassing the expected $365.599 million.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:35 pm

PTVE

Pactiv Evergreen shares are trading lower after the company reported worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:35 pm

HSY

The Hershey Company (NYSE:HSY) reported disappointing Q2 earnings and sales, missing analyst expectations due to a challenging consumer environment. Adjusted EPS fell 36.8% to $1.27, and sales dropped 16.7% to $2.07 billion. The company cited higher commodity costs and lower retailer inventory as key issues. Despite these challenges, Hershey announced quarterly dividends and adjusted its full-year outlook downward.

Portfolio Pulse from Nabaparna Bhattacharya

August 01, 2024 | 12:35 pm

ITRI

Itron has updated its Q3 and FY24 guidance, projecting higher EPS and revenue than previously estimated. For Q3, EPS is expected to be $1.10-$1.20 vs. $0.92 estimated, and revenue is projected at $590M-$600M vs. $586.09M estimated. For FY24, EPS guidance is raised to $4.45-$4.65 vs. $4.07 estimated, and revenue is increased to $2.385B-$2.415B vs. $2.38B estimated.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:33 pm

ETSY

HST

PSA

VOYA

Top Wall Street analysts have downgraded several notable stocks, including Voya Financial, Etsy, Bunge Global, Host Hotels & Resorts, and Public Storage. These downgrades have led to varying impacts on the stock prices of these companies.

Portfolio Pulse from Avi Kapoor

August 01, 2024 | 12:33 pm

AMD

LRCX

Lam Research Corporation (NASDAQ:LRCX) experienced a 2.63% dip in pre-market trading despite strong quarterly earnings and projections. The company reported revenue of $3.87 million and a non-GAAP gross margin of 48.5% for the June 2024 quarter. Despite surpassing analyst revenue predictions for the next quarter, the stock dipped, likely due to high investor expectations. Increased demand for AI-powered chips benefits Lam Research, which competes with Applied Materials, ASML, and KLA Corp.

Portfolio Pulse from Benzinga Neuro

August 01, 2024 | 12:33 pm